Literature DB >> 27459522

Acquired Hemophilia Treated Using Low-Dose of Rituximab.

Nicola Mumoli1, Matteo Giorgi-Pierfranceschi2, Alessandro Ferretti1, Josè Vitale1, Marco Cei1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27459522     DOI： 10.1111/jgs.14188

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN： 0002-8614            Impact factor:   5.562


× No keyword cloud information.
  4 in total

1.  Steroid-resistant autoimmune myelofibrosis in a patient with autoimmune hepatitis and Evans syndrome complicated with increased expression of TGF-β in the bone marrow: a case report.

Authors:  Hiroshi Ohkawara; Miki Furukawa; Kazuhiko Ikeda; Akiko Shichishima-Nakamura; Masahiko Fukatsu; Takahiro Sano; Koki Ueda; Satoshi Kimura; Risa Kanai; Yuka Oka; Fumi Murakami; Osamu Suzuki; Yuko Hashimoto; Kazuei Ogawa; Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2017-06-05       Impact factor: 2.490

2.  Acquired Hemophilia A After SARS-CoV-2 Infection: A Case Report.

Authors:  Jennifer Nardella; Domenico Comitangelo; Renato Marino; Giuseppe Malcangi; Marco Damiano Barratta; Carlo Sabba; Antonio Perrone
Journal:  J Med Cases       Date:  2022-04-12

Review 3.  Targeting Acquired Hemophilia A with Rheumatoid Arthritis by a Rituximab Shot: A Case Report and Review of the Literature.

Authors:  Imad Ghozlani; Aziza Mounach; Mirieme Ghazi; Anass Kherrab; Radouane Niamane
Journal:  Am J Case Rep       Date:  2018-05-21

4.  International recommendations on the diagnosis and treatment of acquired hemophilia A.

Authors:  Andreas Tiede; Peter Collins; Paul Knoebl; Jerome Teitel; Craig Kessler; Midori Shima; Giovanni Di Minno; Roseline d'Oiron; Peter Salaj; Victor Jiménez-Yuste; Angela Huth-Kühne; Paul Giangrande
Journal:  Haematologica       Date:  2020-05-07       Impact factor: 9.941
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.